Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-06-19 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

June 19, 2026 — 02:00 UTC

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the DRC and Uganda has now reached 676 confirmed cases and 136 confirmed deaths as of June 10, remaining the dominant global health emergency with PHEIC status declared May 17. Mood: tense — multiple simultaneous outbreaks (Ebola, hantavirus, Listeria, Salmonella) are straining surveillance systems, while WHO and world leaders push to finalize a landmark Pandemic Agreement before the next crisis.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (ACTIVE PHEIC)

  • As of June 10, 676 confirmed Bundibugyo virus disease (BVD) cases and 136 confirmed deaths have been reported from the DRC, with ongoing cross-border transmission to Uganda. [1]
  • WHO declared BVD a Public Health Emergency of International Concern (PHEIC) on May 17, 2026 — the Bundibugyo strain is distinct from the more familiar Zaire strain and has no fully approved vaccine. [2]
  • Africa CDC and WHO launched a joint continental preparedness and response plan on June 5, aiming to raise US$518 million to support African countries in containing the outbreak. [3]
  • WHO convened expert advisory groups on May 28 to assess candidate vaccines and therapeutics specifically for Bundibugyo virus, as existing mRNA and rVSV platforms were designed primarily for Zaire ebolavirus. [4]
  • CDC has mobilized an international Ebola response and activated enhanced airport screening at Washington-Dulles International Airport (May 21) and Atlanta (May 23) for travelers from affected regions. [5] [6]
  • A joint statement by the DRC government and WHO reaffirmed partnership focused on Ituri Province, where the outbreak originated in Mongbwalu Health Zone. [7]
  • As of the June 18 CDC briefing transcript, CDC also activated a World Cup 2026 monitoring protocol alongside Ebola response, given large-scale international travel to U.S. host cities. [8]

HANTAVIRUS — M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • The Andes hantavirus outbreak linked to cruise ship M/V Hondius began May 2, 2026; as of the fourth WHO Disease Outbreak News report (May 28), case numbers had grown beyond the initial 8 cases with 3 deaths reported by WHO Director-General Tedros on May 7. [9] [10]
  • WHO confirmed the hantavirus involved is the Andes strain — a South American pathogen notable for rare person-to-person transmission potential, unlike most other hantavirus species. [10]
  • Over 120 passengers from 23 countries were safely disembarked in Tenerife, Spain, after international cooperation; WHO DG personally messaged the people of Tenerife thanking them for solidarity. [11]
  • CDC provided multiple daily transcript updates through May 19 and confirmed the risk to the general American public remains extremely low. [12]

LISTERIA — CHICKEN FETTUCCINE ALFREDO MEALS (ACTIVE U.S.)

  • CDC warned on June 19, 2026 (today) of a Listeria monocytogenes outbreak linked to recalled chicken fettuccine alfredo meals, with 17 people sickened from the same strain. [13]
  • A separate active Listeria outbreak linked to requesón and soft ricotta cheese was announced June 5, 2026. [14]

SALMONELLA — MULTIPLE CONCURRENT U.S. OUTBREAKS

  • CDC warned June 16, 2025 of a Salmonella outbreak linked to pistachio cream with 4 confirmed cases; the moringa leaf/moringa powder Salmonella cluster continues to grow, with 65 people across 28 states reported as of January 29, 2026, and an extensively drug-resistant strain identified among moringa powder capsule users. [15] [16] [17]
  • A Salmonella outbreak linked to backyard poultry (13 states, 34 people) was updated in May 2026 showing 150 additional illnesses, with over one quarter of cases in children under 5 years old. [18] [19]

MPOX — CLADE IB/IIB RECOMBINANT STRAIN (GLOBAL WATCH)

  • WHO reported in February 2026 that two cases of a recombinant MPXV strain combining clade Ib and clade IIb genomic elements have been documented — recombination is a known natural process but raises concern about potential changes in transmissibility or immune escape. [20]
  • Broader clade Ib MPXV transmission among men who have sex with men (MSM) in previously unaffected countries was flagged by WHO in December 2025, signaling geographic expansion beyond central Africa. [21]

NIPAH VIRUS — INDIA AND BANGLADESH

  • India reported two confirmed Nipah virus cases in January 2026, both healthcare workers at a private hospital in Barasat, West Bengal (North 24 Parganas district), confirmed at the National Institute of Virology. [22]
  • Bangladesh reported one confirmed Nipah case in Rajshahi Division in February 2026, with onset of fever and neurological symptoms January 21, 2026. [23]

NEW WORLD SCREWWORM — U.S. (ZOONOTIC ALERT)

  • CDC activated its Emergency Operations Center (EOC) for a New World Screwworm response on June 12, 2026 — this parasitic fly (Cochliomyia hominivorax) can infest living tissue in humans and animals and had been considered eradicated from the U.S. [24]

MEASLES — GLOBAL AND U.S.

  • Global measles cases surged to 10.3 million infections in 2023 according to WHO/CDC data, with Bangladesh reporting 19,161 suspected and 2,897 laboratory-confirmed measles cases across 58 of 64 districts as of April 2026. [25] [26]
  • CDC reaffirmed its national measles response through state collaboration in March 2026, following two deaths in the Texas outbreak that began in early 2025. [27] [28]

WHO PANDEMIC AGREEMENT — PATHOGEN ACCESS AND BENEFIT SHARING

  • On June 15, 2026, WHO Director-General Tedros and Brazilian President Lula co-signed an open letter to G7, G20, and BRICS leaders urging urgent finalization of the WHO Pandemic Agreement's Pathogen Access and Benefit Sharing (PABS) annex — the last major unresolved element before the treaty can take force. [29]
  • The letter was addressed from both Geneva and Brasília, reflecting a global north-south co-sponsorship framework designed to overcome stalled negotiations. [29]

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE — POLYAMINE METABOLISM IN KIDNEY REPAIR

  • A new Europe PMC study finds that AMD1-mediated polyamine metabolism governs the fate of tubular repair after kidney injury by restraining cellular senescence — excess senescent cells in kidney tubules impair healing, and modulating this pathway may preserve renal function after acute insult. [30]
  • Polyamines (spermidine, spermine) are increasingly recognized longevity molecules; this work by Mao et al. in Renal Failure (June 14, 2026) suggests AMD1 enzyme activity is a potential therapeutic target. [30]

EPIGENETIC AGING — DNA METHYLATION, TELOMERES, AND ANEURYSM RISK

  • A Mendelian randomization study (Zhang et al., IBRO Neuroscience Reports, published May 30, 2026) used genetic instruments to link DNA methylation-estimated phenotypes and shorter telomere length to increased risk of intracranial aneurysms. [31]
  • The findings suggest that biological aging pace, as measured by epigenetic clocks and telomere attrition, may confer structural vascular risk beyond conventional cardiovascular factors. [31]

REDOX BIOLOGY — ALBUMIN AS AN EXTRACELLULAR AGING SENSOR

  • Ishima et al. (Redox Reports, June 2, 2026) describe serum albumin's Cys34 residue as a dynamic redox sensor; oxidation of this site accumulates with age and disease, and polysulfide-mediated mechanisms help maintain homeostatic redox balance. [32]
  • Oxidized albumin (HNA2 fraction) is emerging as a clinical biomarker of systemic oxidative stress relevant to aging biology and drug-binding capacity. [32]

GRIP STRENGTH AND DIGESTIVE DISEASE LONGEVITY LINK

  • A large prospective parallel analysis in Chinese and European older adults (Liu et al., Global Health Action, June 15, 2026) found that combined low handgrip strength is significantly associated with incident chronic digestive diseases including liver disease and colorectal conditions. [33]
  • Low handgrip strength is a validated sarcopenia marker; this study extends the link between muscle aging and visceral organ health across two ethnically distinct populations. [33]

REPRODUCTIVE AGING — DELAYED CHILDBEARING REVIEW

  • A narrative review by Yang, Huang and He in Journal of Obstetrics and Gynaecology (June 9, 2026) synthesizes evidence on how delayed childbearing accelerates ovarian reserve decline, noting that oocyte quality deteriorates via mitochondrial dysfunction and accumulation of chromosomal errors with age. [34]
  • The authors highlight that women delaying pregnancy past 35 face compounding risks from both chronological and biological reproductive aging, with implications for assisted reproduction counseling. [34]

GUT MICROBIOME — MATERNAL DIET SHAPES NEONATAL NEUROMETABOLIC RESILIENCE

  • Kadyan et al. (Gut Microbes, June 9, 2026) demonstrate in an animal model that maternal dietary patterns program neonatal gut microbiome composition, which in turn shapes neurometabolic resilience — linking prenatal nutrition to postnatal brain and metabolic aging trajectories. [35]
  • The study by Nagpal's group identifies specific microbial taxa and metabolic pathways (short-chain fatty acids, tryptophan metabolism) that mediate these intergenerational effects. [35]

PREBIOTICS AND PHYSICAL FUNCTION IN OBESITY WITH KNEE OSTEOARTHRITIS

  • Wang et al. (Gut Microbes, June 2, 2026) used multi-omics to show that prebiotic supplementation improved physical function markers and metabolic parameters in adults with obesity and knee osteoarthritis, correlating changes with shifts in gut microbial composition. [36]
  • The team (Herzog, Reimer et al., University of Calgary) identified that prebiotic-driven changes in bile acid metabolism and gut permeability markers may underlie improvements in joint-related physical capacity in older adults. [36]

URIC ACID AND FERROPTOSIS — NEUROPROTECTION IN PARKINSON'S MODEL

  • Zhou et al. (Redox Reports, June 4, 2026) show that uric acid alleviates neuroinflammation in LPS-induced BV2 microglia and in an MPTP-induced Parkinson's disease mouse model by resisting ferroptosis through activation of the Nrf2 signaling pathway. [37]
  • Ferroptosis (iron-dependent cell death) is an increasingly recognized mechanism in age-related neurodegeneration; Nrf2 is a master antioxidant transcription factor, and uric acid's role as a natural antioxidant adds nuance to the complex epidemiology of uric acid and Parkinson's risk. [37]

COLLAGEN OXIDATION AND EXTRACELLULAR MATRIX AGING

  • Mathias-Netto et al. (Redox Reports, June 11, 2026) review enzymatic and non-enzymatic oxidative pathways that modify fibrillar collagen — the primary structural protein of connective tissue — noting that oxidation-driven cross-linking stiffens tissue and contributes to age-related fibrosis and organ decline. [38]
  • Both lysyl oxidase-dependent (enzymatic) and reactive oxygen species-driven (non-enzymatic) mechanisms are discussed as targets for anti-fibrotic longevity interventions. [38]

💊 NEW CURES & APPROVALS

Note: openFDA supplemental approvals (SUPPL AP) reflect label expansions or manufacturing updates; dates are pending confirmation from the FDA database. All are listed with active ingredients and sponsors as recorded.

KEYTRUDA (PEMBROLIZUMAB) — MERCK SHARP & DOHME

  • Merck's anti-PD-1 checkpoint inhibitor pembrolizumab (BLA125514) received a supplemental approval — Keytruda now holds one of the broadest oncology indication profiles of any single drug, spanning melanoma, NSCLC, MSI-H tumors, cervical cancer, and numerous other malignancies. [39]

KEYTRUDA QLEX (PEMBROLIZUMAB + BERAHYALURONIDASE ALFA-PMPH) — MERCK SHARP & DOHME

  • Merck's subcutaneous co-formulation of pembrolizumab with berahyaluronidase alfa (BLA761467) received a supplemental approval — this combination enables subcutaneous delivery of pembrolizumab rather than IV infusion, potentially expanding outpatient and home administration. [40]

SKYRIZI (RISANKIZUMAB-RZAA) — ABBVIE INC

  • AbbVie's IL-23 inhibitor risankizumab received supplemental approvals under two separate BLAs (BLA761262 and BLA761105), reflecting label updates across its approved indications in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. [41] [42]

WELIREG (BELZUTIFAN) — MERCK SHARP & DOHME

  • Merck's HIF-2-alpha inhibitor belzutifan (NDA215383) received a supplemental approval; belzutifan is indicated for VHL disease-associated tumors and renal cell carcinoma, acting by blocking the hypoxia-inducible factor pathway that drives tumor angiogenesis. [43]

TRUQAP (CAPIVASERTIB) — ASTRAZENECA

  • AstraZeneca's AKT inhibitor capivasertib (NDA218197) received a supplemental approval; it is indicated in combination with fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer harboring AKT pathway alterations. [44]

TZIELD (TEPLIZUMAB-MZWV) — PROVENTION BIO INC

  • Teplizumab (BLA761183), an anti-CD3 monoclonal antibody that delays clinical type 1 diabetes onset by modulating autoreactive T cells, received a supplemental approval from Provention Bio; this is the only FDA-approved therapy to delay T1D progression in at-risk individuals. [45]

YERVOY (IPILIMUMAB) — BRISTOL MYERS SQUIBB

  • BMS's CTLA-4 checkpoint inhibitor ipilimumab (BLA125377) received a supplemental approval, extending or updating one of its existing indications across melanoma, renal cell carcinoma, or colorectal cancer. [46]

RINVOQ LQ (UPADACITINIB) — ABBVIE

  • AbbVie's JAK1-selective inhibitor upadacitinib in liquid formulation (NDA218347) received a supplemental approval — the liquid form addresses dosing needs in populations unable to swallow tablets, expanding access for pediatric or elderly patients with rheumatoid arthritis, atopic dermatitis, or IBD. [47]

REXTOVY (NALOXONE HYDROCHLORIDE) — AMPHASTAR PHARMACEUTICALS

  • Amphastar's naloxone formulation (NDA208969) received a supplemental approval; naloxone is the opioid overdose reversal agent, and label updates reflect continued efforts to maximize accessibility following CDC data showing a 27% decline in drug overdose deaths in 2024. [48] [49]

PERAMPANEL — TARO PHARMACEUTICALS

  • A generic perampanel (ANDA219052) received an original ANDA approval from Taro, expanding the competitive market for this AMPA-receptor antagonist anti-seizure medication. [50]

LACOSAMIDE — PROD DEVELOPMENT

  • A generic lacosamide (ANDA217596) received an original ANDA approval, adding to the generic supply of this sodium channel-modulating anti-epileptic drug. [51]

🧪 CLINICAL TRIALS

MAP-HEART — HEART FAILURE MULTI-SCALE PHENOTYPING (NCT06280820)

  • This NIH-sponsored observational trial (updated June 18, 2026) enrolls U.S. adults with heart failure — which affects over 6.5 million Americans — to compare blood, imaging, and molecular markers in order to map how HF develops across biological and clinical phenotypes. [52]
  • The multi-scale approach integrates genomics, proteomics, and advanced cardiac imaging to identify aging-related pathways driving HF progression and potential drug targets. [52]

AI-BASED COGNITIVE PREDICTION IN OLDER ADULTS — VIRTUAL REALITY DRIVING (NCT07656389)

  • This new trial (registered June 18, 2026) uses AI analysis of virtual reality driving tasks to predict cognitive capacity in older adults and individuals with mild cognitive impairment (MCI), targeting the phenomenon of "look-but-fail-to-see" attention failures that increase crash risk. [53]
  • The study could yield a non-invasive, scalable screening tool for early cognitive decline detection based on real-world functional behavior. [53]

VIRTUAL REALITY FOR WALKING AND BALANCE IN OLDER ADULTS (NCT07655882)

  • Registered June 18, 2026, this trial tests whether VR-based interactive exercise training outperforms traditional physical therapy for improving gait and balance in older adults, directly targeting fall prevention — a leading cause of injury mortality in aging populations. [54]

SIROLIMUS FOR SLE-ASSOCIATED IMMUNE THROMBOCYTOPENIA (NCT07657793)

  • Registered June 18, 2026, this trial tests sirolimus (an mTOR inhibitor with established longevity biology credentials in animal models) added to standard corticosteroids and hydroxychloroquine for adults aged 18 to 65 with SLE-associated immune thrombocytopenia. [55]
  • The mTOR pathway is a central regulator of cellular aging and immune senescence, making sirolimus repurposing trials doubly significant for the longevity field. [55]

TARGETED TEMPERATURE MANAGEMENT FOR NEUROCOGNITIVE RECOVERY AFTER CANCER SURGERY IN OLDER PATIENTS (NCT07655687)

  • Registered June 18, 2026, this trial examines whether targeted temperature management during major cancer surgery in older adults reduces delayed neurocognitive recovery (dNCR) — a complication associated with prolonged hospital stay, raised morbidity, and accelerated cognitive aging. [56]

ORFORGLIPRON IN ADOLESCENTS WITH OBESITY (NCT06672939 — LILLY)

  • This Eli Lilly-sponsored trial evaluates orforglipron (LY3502970), an oral non-peptide GLP-1 receptor agonist, for efficacy, safety, and pharmacokinetics in adolescents with obesity or overweight with comorbidities, conducted under Master Protocol NCT06672549. [57]
  • Orforglipron is notable as a once-daily oral GLP-1 agonist — unlike semaglutide which requires injection — potentially expanding metabolic-longevity treatment accessibility. [57]

DUPILUMAB FOR BULLOUS PEMPHIGOID (NCT04206553)

  • This Regeneron/Sanofi-sponsored trial (updated June 18, 2026) evaluates dupilumab (anti-IL-4/IL-13 monoclonal antibody) for bullous pemphigoid, an autoimmune blistering skin disease that predominantly affects adults over 70 and carries significant mortality in older populations. [58]

SUCROMET NUTRITIONAL INTERVENTION TRIAL (NCT07656298)

  • Registered June 18, 2026, this trial explores how sucrose and sucralose at low and high doses influence glucose regulation, insulin resistance, and fasting plasma glucose in adults aged 18 to 65 with normal weight, overweight, or obesity. [59]
  • Metabolic dysregulation (insulin resistance) is a primary driver of accelerated biological aging; understanding sweetener effects on glucose homeostasis has direct longevity relevance. [59]

EDINBURGH DIABETES REMISSION STUDY — PANCREAS LIPOTOXICITY IN T2D (NCT07364045)

  • This UK trial investigates how pancreatic fat accumulation drives type 2 diabetes development and whether weight loss can reverse it by lowering intra-pancreatic lipid, potentially restoring beta-cell function and achieving diabetes remission. [60]
  • Previous work (Taylor group, Newcastle) established the "twin cycle" hypothesis of T2D reversibility; this trial builds mechanistic evidence for fat-driven pancreatic senescence as a target. [60]

LOSARTAN TO REDUCE RADIATION-INDUCED FIBROSIS IN BREAST CANCER (NCT05637216)

  • This trial evaluates losartan, an FDA-approved angiotensin receptor blocker and TGF-beta-1 pathway inhibitor, to reduce radiation-induced fibrosis (RIF) in breast and lung tissue after breast cancer radiotherapy. [61]
  • TGF-beta-1 is a central driver of tissue fibrosis and cellular senescence — losartan repurposing bridges cardiovascular aging biology and oncology supportive care. [61]

📢 PUBLIC HEALTH

LISTERIA AND SALMONELLA — ACTIVE U.S. FOOD SAFETY ALERTS

  • CDC urges consumers to check refrigerators and freezers for recalled chicken fettuccine alfredo meals (17 cases, Listeria, announced today June 19) and to avoid requesón/soft ricotta cheese linked to a separate Listeria outbreak announced June 5. [13] [14]
  • CDC warns that moringa leaf products continue to drive a growing, multi-outbreak Salmonella cluster with an extensively drug-resistant strain identified among moringa powder capsule users as of February 2026. [17] [62]

INFANT BOTULISM — NARA ORGANICS FORMULA RECALL

  • CDC on June 13, 2026 urged parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula following confirmation of its link to infant botulism cases — the first infant botulism outbreak linked to powdered formula in CDC records. [63]

UNSAFE FOOD — WHO GLOBAL BURDEN UPDATE

  • WHO released updated estimates on June 4, 2026: unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide, with children under 5 facing nearly three times the risk of foodborne illness compared to older children and adults. [64]

CDC ACIP MEETING — JUNE 25-26, 2025 OUTCOMES

  • The CDC Advisory Committee on Immunization Practices (ACIP) held its June 25-26, 2025 meeting and issued a joint statement; separately, ACIP voted in December 2025 to recommend individual-based decision-making for hepatitis B vaccine for infants born to hepatitis B-negative mothers, a significant departure from universal birth-dose policy. [65] [66]

DRUG-RESISTANT BACTERIA — SHARP RISE REPORTED

  • A CDC report (September 2025) found a dramatic increase in dangerous drug-resistant bacteria in the U.S. — a trend with direct implications for the treatability of post-surgical infections, foodborne illness complications, and outbreak response. [67]

CONGENITAL SYPHILIS — 12TH CONSECUTIVE YEAR OF INCREASE

  • CDC data released September 2026 show U.S. newborn syphilis cases increased for the 12th consecutive year in 2024, reflecting persistent gaps in prenatal STI screening and treatment access. [68]

TRAVEL-RELATED COSMETIC PROCEDURES — ADVERSE OUTCOMES WARNING

  • CDC highlighted on June 2, 2026 a pattern of serious adverse outcomes (infections, disfigurement) linked to travel-related cosmetic procedures obtained abroad, urging consumers to verify credentials and sterile technique standards at international facilities. [69]

BIOMED PULSE is informational only and does not constitute medical advice. All data sourced from WHO, CDC, openFDA, ClinicalTrials.gov, and Europe PMC/PubMed as cited. Consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
  2. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
  3. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  4. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
  5. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
  6. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  7. Joint statement by the Government of the Democratic Republic of the Congo and WHO concerning the outbreak of Ebola disea — WHO News
  8. Transcript - Update on Ebola Outbreak in the Democratic Republic of the Congo and Uganda and CDC's World Cup 2026(TM) ac — CDC Newsroom
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. WHO’s response to hantavirus cases linked to a cruise ship — WHO News
  11. Follow-up message by the WHO Director-General to the people of Tenerife regarding the hantavirus response — WHO News
  12. CDC Provides Update on Hantavirus Outbreak Linked to M/V Hondius Cruise Ship — CDC Newsroom
  13. CDC warns of <em>Listeria</em> outbreak linked to recalled chicken fettuccine alfredo meals — CDC Newsroom
  14. CDC warns of Listeria outbreak linked to requesón/soft ricotta cheese — CDC Newsroom
  15. CDC warns of <em>Salmonella</em> outbreak linked to pistachio cream — CDC Newsroom
  16. New recall in <em>Salmonella</em> outbreak linked to dietary supplements containing moringa leaf powder — CDC Newsroom
  17. Extensively drug-resistant <em>Salmonella</em> outbreak linked to moringa powder capsules — CDC Newsroom
  18. CDC announces <em>Salmonella</em> outbreak in 13 states linked to backyard poultry. — CDC Newsroom
  19. UPDATE - Ongoing <em>Salmonella </em>outbreaks linked to backyard poultry sickens 150 more people with over a quarter of — CDC Newsroom
  20. Mpox: recombinant virus with genomic elements of clades Ib and IIb – Global situation — WHO Disease Outbreak News
  21. Broader transmission of mpox due to clade Ib MPXV – Global situation — WHO Disease Outbreak News
  22. Nipah virus disease - India — WHO Disease Outbreak News
  23. Nipah virus infection - Bangladesh — WHO Disease Outbreak News
  24. CDC Activates Emergency Operations Center for New World Screwworm Response — CDC Newsroom
  25. Measles - Bangladesh — WHO Disease Outbreak News
  26. Measles cases surge worldwide, infecting 10.3 million people in 2023 — CDC Newsroom
  27. CDC Reinforces National Measles Response Through State Collaboration — CDC Newsroom
  28. CDC Statement on Measles Outbreak — CDC Newsroom
  29. Open letter to leaders of G7, G20, BRICS and all nations on finalizing the WHO Pandemic Agreement’s Pathogen Access and — WHO News
  30. AMD1-mediated polyamine metabolism governs tubular repair fate by restraining senescence after kidney injury. — Europe PMC — Longevity
  31. DNA methylation-estimated phenotypes, telomere length, aging and risk of intracranial aneurysms: Evidence from genetic s — Europe PMC — Longevity
  32. Albumin as a dynamic extracellular redox regulator: from Cys34 oxidation biomarkers to polysulfide-mediated homeostatic — Europe PMC — Longevity
  33. Combined handgrip strength and incident chronic digestive diseases: a prospective parallel analysis examining broad and — Europe PMC — Longevity
  34. Delayed childbearing and reproductive ageing: a narrative review. — Europe PMC — Longevity
  35. Maternal diet shapes neonatal microbiome ontogenesis and neurometabolic resilience. — Europe PMC — Longevity
  36. Multiomics insights into the effects of prebiotics on physical function and metabolism in adults with obesity and knee o — Europe PMC — Longevity
  37. Uric acid alleviates the inflammatory response in LPS-induced BV2 cells and MPTP-induced PD mice by resisting ferroptosi — Europe PMC — Longevity
  38. Enzymatic and non-enzymatic oxidation of fibrillar collagen. — Europe PMC — Longevity
  39. KEYTRUDA — MERCK SHARP DOHME — openFDA — Drugs@FDA
  40. KEYTRUDA QLEX — MERCK SHARP DOHME — openFDA — Drugs@FDA
  41. SKYRIZI — ABBVIE INC — openFDA — Drugs@FDA
  42. SKYRIZI — ABBVIE INC — openFDA — Drugs@FDA
  43. WELIREG — MERCK SHARP DOHME — openFDA — Drugs@FDA
  44. TRUQAP — ASTRAZENECA — openFDA — Drugs@FDA
  45. TZIELD — PROVENTION BIO INC — openFDA — Drugs@FDA
  46. YERVOY — BRISTOL MYERS SQUIBB — openFDA — Drugs@FDA
  47. RINVOQ LQ — ABBVIE — openFDA — Drugs@FDA
  48. REXTOVY — AMPHASTAR PHARMS INC — openFDA — Drugs@FDA
  49. Statement from CDC's National Center for Injury Prevention and Control on Provisional 2024 Overdose Death Data — CDC Newsroom
  50. PERAMPANEL — TARO — openFDA — Drugs@FDA
  51. LACOSAMIDE — PROD DEVELOPMENT — openFDA — Drugs@FDA
  52. Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART) — ClinicalTrials.gov — Aging
  53. An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtu — ClinicalTrials.gov — Aging
  54. Virtual Reality for Walking and Balance in Older Adults — ClinicalTrials.gov — Aging
  55. Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia — ClinicalTrials.gov — Aging
  56. Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery — ClinicalTrials.gov — Aging
  57. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities — ClinicalTrials.gov — Aging
  58. A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid — ClinicalTrials.gov — Aging
  59. SucroMet Nutritional Intervention Trial — ClinicalTrials.gov — Aging
  60. Pancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS) — ClinicalTrials.gov — Aging
  61. Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients — ClinicalTrials.gov — Aging
  62. Alert Update: Growing number of Salmonella illnesses and outbreaks linked to moringa leaf products — CDC Newsroom
  63. CDC Outbreak Update: Infant Botulism Linked to Powdered Infant Formula — CDC Newsroom
  64. Unsafe food causes 866 million illnesses and 1.5 million deaths annually, young children at highest risk — WHO News
  65. CDC's Advisory Committee on Immunization Concludes Meeting with Joint Statement — CDC Newsroom
  66. ACIP Recommends Individual-Based Decision-Making for Hepatitis B Vaccine for Infants Born to Women Who Test Negative for — CDC Newsroom
  67. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria — CDC Newsroom
  68. CDC Reports Latest National Data on Syphilis in Newborns and Sexually Transmitted Infections (STIs) — CDC Newsroom
  69. CDC Highlights Adverse Outcomes Linked to Travel-Related Cosmetic Procedures — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260619-02-v5 · 2026-06-19 02:02 UTC

Read next